Compare Goldman Sachs Physical Gold ETF (AAAU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Novo Nordisk A/S — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.36, while Novo Nordisk A/S trades at $46.56 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Goldman Sachs Physical Gold ETF pays none, and Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| AAAU | NVO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $63.98 |
52-Week Low | $32.74 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $43.52, up 0.58% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold hitting $4,438/oz. The stock lacks disclosed financial ratios, indicating potential data gaps for fundamental analysis.
The outlook for AAAU is tied to gold's momentum, supported by Fed policy expectations and safe-haven demand, but risks include volatility from economic data and overbought conditions. Investors should weigh gold's bullish trends against the absence of company-specific fundamentals and high RSI levels suggesting near-term caution.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
